Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine

References

• ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 ReportJAMA20032892560257212748199
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension-European Society of Cardiology Guidelines Committee2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertensionJ Hypertens2003211011105312777938
   PubMed Web of Science ®Google Scholar
• TurnbullEEffects of different blood-pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet20033621527153514615107
   PubMed Web of Science ®Google Scholar
• StaessenJAWangJGThijsLCardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 1, 2003J Hypertens2003211055107612777939
   PubMed Web of Science ®Google Scholar
• HanssonLZanchettiACarruthersSGfor the HOT study groupEffects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trialLancet1998351175517629635947
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupTight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ19983177037139732337
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJBoschJDaviesRDagenaisGfor the Heart Outcomes Prevention Evaluation Study InvestigatorsEffects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patientsN Engl J Med200034214515310639539
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupMajor outcomes in high-risk patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)JAMA20022882981299712479763
   PubMed Web of Science ®Google Scholar
• MoserMBlackHRThe role of combination therapy in the treatment of hypertensionAm J Hypertens19981173S78S9655566
   PubMed Web of Science ®Google Scholar
• SicaDARationale for fixed dose combinations in the treatment of hypertension: the cycle repeatsDrugs20026244346211827559
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakAfor the Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology2007Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens20072511051187 Erratum in: J Hypertens. 2007;25:1749.17563527
   PubMed Web of Science ®Google Scholar
• KjeldsenSEAksnesTAde la SierraAAmlodipine and valsartan: calcium channel blockers/angiotensin II receptor blockers combination for hypertensionTherapy200743140
   Google Scholar
• DagenaisNJJamaliFProtective effects of angiotensin II interruption: evidence for antiinflammatory actionsPharmacotherapy2005251213122916164395
   PubMed Web of Science ®Google Scholar
• BakrisGLCombined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blockerJ Clin Hypertens (Greenwich)2008101 Suppl 1273218174781
   PubMed Web of Science ®Google Scholar
• FogariRZoppiADerosaGEffect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patientsJ Hum Hypertens20072122022417215848
   PubMed Web of Science ®Google Scholar
• PhilippTSmithTRGlazerRTwo multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertensionClin Ther20072956358017617280
   PubMed Web of Science ®Google Scholar
• HanssonLHednerTDahlöfBProspective randomized open blinded end-point (PROBE) study. A novel design for intervention trialsBlood Press199211131191366259
   PubMedGoogle Scholar
• ParatiGBosiSCastellanoMGuidelines for 24 hour non invasive ambulatory blood pressure monitoring: report from a working group of the Italian Society of HypertensionHigh Blood Press19954168174
   Google Scholar
• OmboniSParatiGZanchettiAManciaGCirculation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspectsJ Hypertens199513110511128586802
   PubMed Web of Science ®Google Scholar
• RizzoniDCastellanoMMuiesanMLPorteriEAgabiti RoseiEBeyond trough:peak ratio. A new index of the smoothness of the anti-hypertensive effect of a drugHigh Blood Press19976110115
   Google Scholar
• ParatiGOmboniSTizzoniDAgabiti RoseiEManciaGThe smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertensionJ Hypertens199816168516919856370
   PubMed Web of Science ®Google Scholar
• GokhaleNShahaniSPawarDEfficacy and safety of losartan-amlodipine combination – an Indian postmarketing surveillance experienceJ Indian Med Assoc2002100320720812408291
   PubMedGoogle Scholar
• KohlmannOJrOigmanWMionDJrThe “LOTHAR” study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertensionArq Bras Cardiol200686395116491208
   PubMedGoogle Scholar
• AllemannYFraileBLambertMBarbierMFerberPIzzoJLJrEfficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) studyJ Clin Hypertens (Greenwich)20081018519418326958
   PubMed Web of Science ®Google Scholar
• GregLPloskerGLRobinsonDMAmlodipine/valsartan: fixed-dose combination in hypertensionDrugs20086837328118257612
   PubMed Web of Science ®Google Scholar
• ChungOCsikósTUngerTAngiotensin II receptor pharmacology and AT1-receptor blockersJ Hum Hypertens199913Suppl 1S112010076916
   PubMedGoogle Scholar
• MazzolaiLMaillardMRossatJNussbergerJBrunnerHRBurnierMAngiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonistsHypertension19993385085510082498
   PubMed Web of Science ®Google Scholar
• StamlerRImplications of the INTERALSALT. StudyJ Hypertens199117Suppl 1116120
   Google Scholar
• LewingtonSClarkeRQizilbashNPetoRCollinsRfor the Prospective Studies CollaborationAge-specific relevance of usual blood pressure to vascular mortality. A meta analysis of individual data for one million adults in 61 prospective studiesLancet20023601903191312493255
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMfor the VALUE trial GroupOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or anlodipine:the value randomised trialLancet20043632022203115207952
   PubMed Web of Science ®Google Scholar
• PalatiniPPenzoMRacioppaAClinical relevance of nighttime blood pressure and of daytime blood pressure variabilityArch Intern Med1992152185518601387782
   PubMed Web of Science ®Google Scholar